News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Niklas Klümper: Trastuzumab deruxtecan achieving high ORR in patients with advanced HER2-amplified solid tumors
globaloncologyacademy.org
Nov 11, 2024, 23:44

Niklas Klümper: Trastuzumab deruxtecan achieving high ORR in patients with advanced HER2-amplified solid tumors

Niklas Klümper, Senior Consultant for Urology and GU Oncology at University Hospital Bonn, shared a post on X:

“New data shows T-DXd achieving high ORR with durable response in patients with advanced HER2-amplified solid tumors, as determined by cfDNA testing!

A strong example of an elegant biomarker-based basket design, further supporting tumor-agnostic approval of T-DXd for HER2-positive cancers.”

Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial.

Authors: Masataka Yagisawa, Hiroya Taniguchi, Taroh Satoh, Shigenori Kadowaki, Yu Sunakawa, Tomohiro Nishina, Yoshito Komatsu, Taito Esaki, Daisuke Sakai, Ayako Doi, Takeshi Kajiwara, Hiromi Ono, Masatoshi Asano, Nami Hirano, Justin Odegaard, Satoshi Fujii, Shogo Nomura, Hideaki Bando, Akihiro Sato, Takayuki Yoshino, Yoshiaki Nakamura

Niklas Klümper

Akihiro Sato Ayako Doi cancer cfDNA testing Daisuke Sakai HER2-positive cancers Hideaki Bando Hiromi Ono Hiroya Taniguchi Justin Odegaard Masataka Yagisawa Masatoshi Asano Nami Hirano Niklas Klümper OncoDaily Oncology Satoshi Fujii Shigenori Kadowaki Shogo Nomura solid tumors Taito Esaki Takayuki Yoshino Takeshi Kajiwara Taroh Satoh Tomohiro Nishina Trastuzumab deruxtecan Yoshiaki Nakamura Yoshito Komatsu Yu Sunakawa
Special Coverage
Blog
Dec 21, 2024, 12:18
NCI Symposium on Translational Technology for Global Health
Blog
Dec 21, 2024, 12:14
Paolo Tarantino: Ending of a terrific 3-year cycle of PhD at The University of Milan
Blog
Dec 21, 2024, 11:52
Gevorg Tamamyan's first message as New POEM President
Blog
Dec 21, 2024, 11:30
Kyaw Thein: Tissue-Agnostic Drug Development in Cancer
Dialogues
Dec 21, 2024, 11:29
Beyond the Cancer Diagnosis: Dialogue with Marianne Arab, Hosted by Adrian Pogacian
Blog
Dec 21, 2024, 11:27
Aleix Prat: Carlos Fernandez de Larrea has been appointed as a Professor at the University of Barcelona
Blog
Dec 21, 2024, 11:25
Canadian Cancer Society - Natalie Wild's caregiver story
Blog
Dec 21, 2024, 11:24
Christy Brown: How many things can you dread more than 'your child has aggressive brain cancer?'
Blog
Dec 21, 2024, 11:18
Jose Fernando Moura: Pivotal SABCS24 summary hosted by Cancer Network
Blog
Dec 21, 2024, 11:18
Jérôme Salomon: President Macron, WHO Director-General and global health leaders inaugurate WHO Academy
Blog
Dec 21, 2024, 11:17
ChatGPT-Like AI Tool Promises to Speed Treatment Advances and Free Doctors’ Time by Matching Patients with Clinical Trials
Blog
Dec 21, 2024, 11:14
Mediamedic - Wenbin Zhou on Pyrotinib-based regimen in HER2-positive breast cancer